Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2002-09-12
2008-03-11
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S021800, C530S313000, C530S399000
Reexamination Certificate
active
07341989
ABSTRACT:
The invention provides a new use for LH, and analogues having LH-activity for aiding folliculogenesis in controlled ovarian hyperstimulation (COH), in which the LH or an analogue thereof is administered during a priming period lasting from day 1 to about day 4 of the stimulatory phase in COH.
REFERENCES:
patent: 5650390 (1997-07-01), Samaritani et al.
patent: 0 170 502 (1991-06-01), None
patent: WO-00/67778 (2000-11-01), None
Rudinger, Peptide Hormones, (Jun. 1976) 1,5-6.
Richard L. Stouffer and Mary B. Zelinski-Wooten, Overriding follicle selection in controlled ovarian stimulation protocols: Quality vs. quantity, Reproductive Biology and Endocrinology, 2004, vol. 2, No. 32, pp. 1-12.
Kousta et al, “Successful Induction of Ovulation and Completed Pregnancy Using Recombinant Human Luteinizing Hormone and Follicle Stimulation Hormone in a Woman with Kallmann's Syndrome”, Human Reproduction, 1996, pp. 70-71, col. 11, No. 1.
Deyo et al, “The Use of GnRH or LH to Synchronise Follicular Wave Emergence for Superstimulation in Cattle” Theriogenology, 2001, pp. 513, vol. 55.
Marco Filicori, M.D., “The Role of Luteinising Hormone in Folliculogenesis and Ovulation Induction”, Fertility & Sterility, 1999, pp. 405-414, vol. 1999.
“Recombinant Human Luteinising Hormone is as Effictive as, but Safer than, Urinary Human Chorionic Gonadotropin in Inducing Final Follicular Maturation and Ovulation in In Vitro Fertilization Procedures: Results of a Multicenter Double-Blind Study”, J. Clin. Endocrinol. & Metabol., 2001, pp. 2607-2618, vol. 86.
David Lindsay Healy et al, “Female Infertility: Causes and Treatment”, The Lancet, 1994, pp. 1539-1544, vol. 343.
Marco Filicori, “Gonadotropin-Releasing Hormone Analogs in Ovulation Induction: Current Status and Perspectives”, Journal of Clinical Endocrinology and Metabolism, 1996, pp. 2413-2416, vol. 81.
Marco Filicori et al, “Different Gonadotropin and Leuprorelin Ovulation Induction Regimens Markedly Affect Follicular Fluid Hormone Levels and Folliculogenesis”, Fertility and Sterility, Feb. 2, 1996, pp. 387-393, vol. 65.
M. Filicori et al, “Luteinizing Hormone Activity Supplementation Enhances Follicle-Stimulating Hormone Efficacy and Improves Ovulation Induction Outcome”, The Journal of Clinical Endocrinology & Metabolism, 1999, pp. 2659-2663, vol. 84.
“Recombinant Human Luteinizing Hormone (LH) to Support Recombinate Human Follicle-Stimulating Hormone (FSH)- Induced Follicular Development in LH- and FSH-Deficient Anovulatory Women: A Dose-Finding Study”, Journal of Clinical Endocrinology and Metabolism, 1998, pp. 1507-1514, vol. 83.
Michael W. Sullivan et al, “Ovarian Responses in Women to Recombinant Follicle-Stimulating Hormone and Luteinizing Hormone (LH): A Role for LH in the Final Stages of Follicular Maturation”, Journal of Clinical Endocrinology and Metabolism, 1999, pp. 228-232,vol. 84.
E. Scott Sills et al, “A Prospective Randomized Comparison of Ovulation Induction Using Highly purified Follicle-Stimulating Hormone Alone and with Recombinant Human Luteinizing Hormone in In-Vitro Fertilization”, Human Reproduction, 1999, pp. 2230-2235, vol. 14.
Ben-Amor A-F, et al, “The Effect of Luteinizing Hormone Administered During Late Follicular Phase in Normo-Ovulatory Women Undergoing In-Vitro Fertilization”, Human Reproduction, 2000, pp. 46, Abstract book 1, Abstract No. O-032.
L. Werlin et al, “A Multi-Center, Randomized, Comparative, Open-Label Trial to Assess the Safety and Efficacy of Gonal-F (r-hFSH) Versus Gonal-F and Recombinant Human Lutenizing Hormone (r-hLH) in Patients Undergoing ICSI: Preliminary Data”, Fert. Steril., Sep. 1999, pp. S12, vol. 72, Abstract No. O-032.
R.S. Williams, “A Multi-Center Study Comparing the Efficacy of Recombinant Human Follicle Stimulating Hormone (r-hFSH, Gonal-F) Versus r-hFSH Plus Recombinant Human Luteinizing Hormone (r-hLH, Lhadi) in Patients Undergoing Controlled Ovarian Hyperstimulation (COH) for Assisted Reproductive Technologies (ART)”, Fertil. Steril., 2000, pp. S228, vol. 74, Abstract No. p. 428.
H. Van Hell et al, “Effects of Human Menopausal Gonadotrophin Preparations in Different Bioassay Methods”, Acta Endocrin, 1964, pp. 409-418, vol. 47.
Ludwig et al., Use of recombinant human chorionic gonadotropin in ovulation induction, Fertility and Sterility, 79(5) 1051-1059 (May 2001).
Hillier Stephen G.
Howles Colin Michael
Browdy and Neimark PLLC
Harle Jennifer I
Laboratories Seronosa
Tate Christopher R.
LandOfFree
Use of LH in controlled ovarian hyperstimulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of LH in controlled ovarian hyperstimulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of LH in controlled ovarian hyperstimulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3980831